A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists
MC Michel, C Foster, HR Brunner, L Liu - Pharmacological reviews, 2013 - ASPET
Angiotensin II type 1 receptor antagonists (ARBs) have become an important drug class in
the treatment of hypertension and heart failure and the protection from diabetic nephropathy …
the treatment of hypertension and heart failure and the protection from diabetic nephropathy …
Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development
SF Zhou, ZW Zhou, LP Yang… - Current medicinal …, 2009 - ingentaconnect.com
Cytochrome P450 2C9 (CYP2C9) is one of the most abundant CYP enzymes in the human
liver. CYP2C9 metabolizes more than 100 therapeutic drugs, including tolbutamide …
liver. CYP2C9 metabolizes more than 100 therapeutic drugs, including tolbutamide …
Excretion and ecotoxicity of pharmaceutical and personal care products in the environment
PK Jjemba - Ecotoxicology and environmental safety, 2006 - Elsevier
The presence and fate of pharmaceutical and personal care products (PPCPs) in the
environment is undergoing increasing scrutiny. The existing clinical pharmacokinetics and …
environment is undergoing increasing scrutiny. The existing clinical pharmacokinetics and …
Clinical pharmacokinetics and pharmacodynamics of aliskiren
S Vaidyanathan, V Jarugula, HA Dieterich… - Clinical …, 2008 - Springer
Aliskiren is the first orally bioavailable direct renin inhibitor approved for the treatment of
hypertension. It acts at the point of activation of the renin-angiotensin-aldosterone system, or …
hypertension. It acts at the point of activation of the renin-angiotensin-aldosterone system, or …
Exposure assessment of pharmaceuticals and their metabolites in the aquatic environment: application to the French situation and preliminary prioritization
JP Besse, C Kausch-Barreto, J Garric - Human and Ecological …, 2008 - Taylor & Francis
Low levels of pharmaceuticals have been detected in many countries in surface waters. As a
wide range of pharmaceuticals can reach aquatic environments, a selection of molecules to …
wide range of pharmaceuticals can reach aquatic environments, a selection of molecules to …
[图书][B] Pharma-ecology: the occurrence and fate of pharmaceuticals and personal care products in the environment
PK Jjemba - 2018 - books.google.com
The revised edition of the guide to environmental impact of pharmaceuticals and personal
care products The revised and updated second edition of Pharma-Ecology joins the health …
care products The revised and updated second edition of Pharma-Ecology joins the health …
Clinical pharmacokinetics of sacubitril/valsartan (LCZ696): a novel angiotensin receptor-neprilysin inhibitor
S Ayalasomayajula, T Langenickel, P Pal… - Clinical …, 2017 - Springer
Abstract Sacubitril/valsartan (LCZ696) is indicated for the treatment of heart failure with
reduced ejection fraction. Absorption of sacubitril/valsartan and conversion of sacubitril …
reduced ejection fraction. Absorption of sacubitril/valsartan and conversion of sacubitril …
Identification of cytochrome P450 forms involved in the 4-hydroxylation of valsartan, a potent and specific angiotensin II receptor antagonist, in human liver …
A Nakashima, H Kawashita, N Masuda, C Saxer… - Xenobiotica, 2005 - Taylor & Francis
Valsartan is known to be excreted largely as unchanged compound and is minimally
metabolized in man. Although the only notable metabolite is 4-hydroxyvaleryl metabolite (4 …
metabolized in man. Although the only notable metabolite is 4-hydroxyvaleryl metabolite (4 …
In vitro and in vivo interaction studies between lesinurad, a selective urate reabsorption inhibitor, and major liver or kidney transporters
Z Shen, LT Yeh, K Wallach, N Zhu, B Kerr… - Clinical drug …, 2016 - Springer
Abstract Background and Objectives Lesinurad is a selective uric acid reabsorption inhibitor
(SURI) under investigation for the treatment of gout. This study elucidated the interaction of …
(SURI) under investigation for the treatment of gout. This study elucidated the interaction of …
Drug interactions with angiotensin receptor blockers: a comparison with other antihypertensives
T Unger, E Kaschina - Drug Safety, 2003 - Springer
The ever-increasing introduction of new therapeutic agents means that the potential for drug
interactions is likely to escalate. Numerous different classes of drugs are currently used to …
interactions is likely to escalate. Numerous different classes of drugs are currently used to …